Astragaloside IV Attenuates Heart Failure by Modulating SCAD/DJ-1/SIRT1/FOXO3a Signaling Axis.

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Pharmacology

Background:

• Astragaloside IV (AS-IV), derived from Astragalus, shows promise for heart failure (HF).
• The role of Short-chain Acyl-CoA dehydrogenase (SCAD) in fatty acid oxidation and its link to HF are established.
• The precise molecular mechanisms of AS-IV in modulating myocardial energy metabolism during HF are not fully understood.

Purpose of the Study:

• To elucidate the underlying mechanisms of AS-IV's cardioprotective effects in HF.
• To investigate AS-IV's influence on myocardial energy metabolism and cardiomyocyte apoptosis.
• To explore the potential of AS-IV as a therapeutic agent for HF.

Main Methods:

• Established an in vivo HF mouse model using transverse aortic constriction (TAC).
• Utilized in vitro H9C2 cardiomyocyte models with tert-butyl hydroperoxide (tBHP) stimulation.
• Performed gene silencing of SCAD or DJ-1 using small interfering RNA (siRNA).

Main Results:

• AS-IV significantly improved cardiac function, reduced myocardial fibrosis, and enhanced energy metabolism in HF mice.
• AS-IV treatment decreased cardiomyocyte apoptosis and oxidative stress in both in vivo and in vitro models.
• AS-IV was found to activate the SCAD/DJ-1/SIRT1/FOXO3a signaling axis, a mechanism validated by gene silencing experiments.

Conclusions:

• AS-IV ameliorates HF by improving myocardial energy metabolism, reducing oxidative stress, and inhibiting cardiomyocyte apoptosis.
• The protective effects of AS-IV are mediated through the activation of the SCAD/DJ-1/SIRT1/FOXO3a signaling pathway.
• AS-IV demonstrates significant potential as a therapeutic strategy for managing heart failure.